ONCOTHERAPEUTICS PLANS PHASE II OTx-287 STUDIES IN RENAL, COLORECTAL
ONCOTHERAPEUTICS PLANS PHASE II OTx-287 STUDIES IN RENAL, COLORECTAL and either brain or melanoma cancers in the next 12 to 18 months, Exec VP-R&D Frank Pilkiewicz, PhD, told a Mabon Securities conference on cell therapy, gene therapy and drug delivery companies in New York City Feb. 16. Pilkiewicz described OTx-287 as a "proteo-liposome formulation" of interleukin-2. Recombinant IL-2 is marketed by Chiron for treatment of metasiatic renal cell carcinoma as Proleukin.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth